102 reports of this reaction
3.0% of all BENZALKONIUM CHLORIDE 0.13% reports
#16 most reported adverse reaction
TREATMENT FAILURE is the #16 most commonly reported adverse reaction for BENZALKONIUM CHLORIDE 0.13%, manufactured by Meijer, Inc.. There are 102 FDA adverse event reports linking BENZALKONIUM CHLORIDE 0.13% to TREATMENT FAILURE. This represents approximately 3.0% of all 3,369 adverse event reports for this drug.
Patients taking BENZALKONIUM CHLORIDE 0.13% who experience treatment failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREATMENT FAILURE is a less commonly reported adverse event for BENZALKONIUM CHLORIDE 0.13%, but still significant enough to appear in the safety profile.
In addition to treatment failure, the following adverse reactions have been reported for BENZALKONIUM CHLORIDE 0.13%:
The following drugs have also been linked to treatment failure in FDA adverse event reports:
TREATMENT FAILURE has been reported as an adverse event in 102 FDA reports for BENZALKONIUM CHLORIDE 0.13%. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREATMENT FAILURE accounts for approximately 3.0% of all adverse event reports for BENZALKONIUM CHLORIDE 0.13%, making it a notable side effect.
If you experience treatment failure while taking BENZALKONIUM CHLORIDE 0.13%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.